CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Samsung Bioepis Co., Ltd. vs. Genentech, Inc.

πŸ“‘ 5G SEP β€’ ETSI Declared

Explore the PTAB proceeding IPR2017-02139 filed by Samsung Bioepis Co., Ltd. on 2017-09-29. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2017-02139

Filing Date

2017-09-29

Accorded Filing Date

2017-10-05

Institution Decision Date

2018-02-22

Last Modified Date

β€”

Proceeding Type

IPR

Termination Date

2018-11-29

Trial Status

Final Written Decision

Parties & Counsel

Patent Owner / Respondent

Patent Information

1 Patent Involved
Respondent Application Number 08146206
Respondent Patent Number 6407213
Legal Expiration Date
2020-06-30 Expired (Term Ended)
Patent Term Adjustment (PTA) +2937 Days Awarded
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred
Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Tribunal & APJ Panel Intelligence

Board Intelligence

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Decisions Rendered

1 Total

Proceeding Status

Final Written Decision

Administrative Patent Judges (APJ Panel)

Panel assignment tracked upon institution decision entry

Board Decisions & Rulings (1)

Final Decision 2018-11-29
Final Written Decision
35 USC 318, 35 USC 312, 37 CFR 42.5, 37 CFR 42.73

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 6 proceedings
πŸ›οΈ
USPTO PTAB Trials 8 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (1): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (14 found):
PTAB: 8 U.S. Courts: 6
USPTO PTAB Trial 2017-08-31
IPR2017-02031

Boehringer Ingelheim Pharmaceuticals, Inc. et al. v. Genentech, Inc.

Asserted Patent
Status: Terminated
USPTO PTAB Trial 2017-08-31
IPR2017-02032

Boehringer Ingelheim Pharmaceuticals, Inc. et al. v. Genentech, Inc.

Asserted Patent
Status: Terminated
USPTO PTAB Trial 2017-05-25
IPR2017-01489

Pfizer, Inc. v. Genentech, Inc.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2017-05-25
IPR2017-01488

Pfizer, Inc. v. Genentech, Inc.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2017-05-08
IPR2017-01373

Celltrion Inc. et al. v. Genentech, Inc.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2017-05-08
IPR2017-01374

Celltrion Inc. et al. v. Genentech, Inc.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2016-08-30
IPR2016-01693

Mylan Pharmaceuticals Inc. et al. v. Genentech, Inc.

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2016-08-30
IPR2016-01694

Mylan Pharmaceuticals Inc. et al. v. Genentech, Inc.

Asserted Patent
Status: Terminated-Settled
U.S. District Court 2019-04-05
1:19-cv-00638

Genentech, Inc. v. Pfizer Inc.

Asserted Patent
Status: DED
U.S. District Court 2019-03-29
1:19-cv-00602

Genentech, Inc. v. Immunex Rhode Island Corp.

Asserted Patent
Status: DED
U.S. District Court 2018-09-04
1:18-cv-01363

Genentech, Inc. v. Samsung Bioepis Co., Ltd.

Asserted Patent
Status: DED
U.S. District Court 2018-01-12
1:18-cv-00095

Genentech, Inc. v. Celltrion, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-10-18
1:17-cv-01471

Genentech, Inc. v. Amgen, Inc.

Asserted Patent
Status: DED
U.S. District Court 2017-10-06
1:17-cv-01407

Genentech, Inc. v. Amgen Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP β€’ ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 5G NR Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Samsung

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.

βœ“ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
βœ“ Right to demand global FRAND portfolio determination.
βœ“ Non-discrimination defense: check licensing terms offered to competing implementers.

Proceeding Documents

200
12

Final Written Decision Paper

2018-11-29 FILING PARTY: BOARD
11

Decision - Institution of Inter Partes Review and Grant of Motion for Joinder Paper

2018-02-22 FILING PARTY: BOARD
10

Patent Owner's Second Mandatory Notice Paper

2018-02-02 FILING PARTY: PATENT OWN
9

Patent Owner's Updated Mandatory Notices Paper

2017-11-29 FILING PARTY: PATENT OWN
8

Petitioner's Reply to Patent Owner's Opposition to Motion for Joinder Paper

2017-11-27 FILING PARTY: PETITIONER

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc